Fulcrum Therapeutics Names Alan Musso Principal Accounting Officer

What Happened

• Fulcrum Therapeutics (FULC) filed an 8-K on August 10, 2026 confirming that Greg Tourangeau, Vice President, Finance and principal accounting officer, will leave his roles effective August 7, 2026.
• On August 9, 2026, Fulcrum’s Board appointed Alan Musso, the company’s Chief Financial Officer and principal financial officer, as principal accounting officer effective August 7, 2026 (upon Mr. Tourangeau’s departure).

Key Details

• Departure date for Greg Tourangeau: August 7, 2026 (previously disclosed in an 8-K on June 11, 2026).
• Appointment: Alan Musso named principal accounting officer by the Board on August 9, 2026, effective August 7, 2026.
• Compensation and disclosures: Mr. Musso will receive no additional compensation for this role; no arrangements or understandings with other persons were disclosed; no family relationships or reportable related-party transactions were noted.
• Biographical info for Mr. Musso is incorporated by reference from Fulcrum’s Schedule 14A proxy filed April 30, 2026.

Why It Matters

• The change consolidates the principal accounting officer role with the company’s CFO, which may affect who signs and oversees financial reporting and controls going forward.
• For investors, this is an internal succession with no disclosed extra pay or related-party concerns, indicating continuity in the finance leadership and no immediate change to compensation expense or governance disclosures.